| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10909295 | Leukemia Research | 2011 | 9 Pages |
Abstract
In conclusion, AML blasts do express pro-apoptotic TRAIL receptors. However, co-expression of decoy receptor TRAIL-R3 results in significant shortened overall survival. AML blasts could be targeted by anti-TRAIL-R2 antibodies, yielding a new therapeutic option for AML patients.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
M.E.D. Chamuleau, G.J. Ossenkoppele, A. van Rhenen, L. van Dreunen, S.M.G. Jirka, A. Zevenbergen, G.J. Schuurhuis, A.A. van de Loosdrecht,